To transform patients’ lives with ocular diseases, Theialife develops safe and effective therapies. Our goal is to successfully advance and seek marketing approval for innovative ocular cancer treatments. We also want to provide patients with broad access to our future products. We plan to initiate clinical trials on humans to assess the safety and effectiveness of our first investigational drug candidate for pediatric myopia. Early access, also known as compassionate use, allows patients to obtain investigational products without clinical trials or market approval. This is when no alternative therapies are available. In these instances, a patient’s treating physician can request an investigational product prior to regulatory approval, where allowed by local laws.

Currently open to enroll patients in the following participating countries: UK, Australia

If you are a healthcare provider interested in learning more about our investigational therapies, or a physician with questions about joining our early access program in the UK or Australia, please submit your request in the form below.

The company will respond to questions as soon as possible. This policy may be revised at any time by Theialife. We continue to push forward in our development programs with the goal of delivering innovative products to the largest number of patients in the shortest amount of time.

Disclaimer: The US FDA or the European Medicines Agency has not confirmed ND10 as safe and effective for its specific indications. Additionally, the investigational medical product may or may not treat the condition.

Despite the absence of adverse events reported over the past 14 years, it is still possible that the product could cause unexpected or serious side effects as a result of its use. Please consult your healthcare provider.